TICKERNERD
Menu
TLSATLSAHealthcare · Biotechnology

TLSA Stock Forecast: Tiziana Life Sciences Ltd. (Bermuda) Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.90
−4.77% on the day

The 2 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) hold a median 12-month price target of $8.03 — +787.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 29 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$110.7M
Ticker Nerd rank
20/ 100
Median analyst target
$8.03
Analysts covering
2
Total return, dividends reinvested
1W
−9.5%
1M
−4.8%
YTD
−39.3%
1Y
−52.1%
From 52W high
−52.9%
From 52W low
+17.5%
$0.77
$1.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tiziana Life Sciences Ltd. (Bermuda) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
20/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Size
72
Volatility
56
Value
48
Revisions
27
Growth
24
Issuance
15
Momentum
14
Quality
11

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TLSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26TLSAHigh $9.03Median $8.03Low $7.03

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $7.03Median $8.03High $9.03

The green dot is the last close — the median target sits +787.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026BTIGReiteratesBuy$7.00
3 Sept 2026BTIGInitiatesBuy$7.00
3 Sept 2026BTIGInitiatesBuy—
6 Sept 2022ThinkEquityInitiatesBuy—
13 June 2022ThinkEquityInitiatesBuy—
12 Apr 2021Zacks Investment ResearchInitiatesNot Rated—
21 Sept 2020HC Wainwright & Co.MaintainsBuy$25 → $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TLSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TLSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Tiziana Life Sciences Ltd. (Bermuda) returned −52.1% against +13.1% for the S&P 500, dividends included.

TLSA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TLSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tiziana Life Sciences Ltd. (Bermuda) (TLSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
14.4×

Cheaper than 6% of US stocks

EV / EBITDA
−4.7×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−780.6%

Higher than 2% of US stocks

Return on assets
−103.2%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tiziana Life Sciences Ltd. (Bermuda) (TLSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tiziana Life Sciences Ltd. (Bermuda) has a market value of $110.7M and an enterprise value of $109.4M.

  • Shares outstanding: 120.5M.

  • Trailing P/E: −5.5×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tiziana Life Sciences Ltd. (Bermuda) employs 10 people.

market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

TLSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TLSATiziana Life Sciences Ltd. (Bermuda)$110.7M20
NKTXNkarta, Inc.$118.3M43
PYPDPolyPid Ltd.$113.5M75
ARMPArmata Pharmaceuticals, Inc.$119.1M71
OTLKOutlook Therapeutics, Inc.$120.1M4
AVXLAnavex Life Sciences Corp.$120.5M22
NRXPNRX Pharmaceuticals, Inc.$111.6M15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tiziana Life Sciences Ltd. (Bermuda) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLSA news & analysis

Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab

Proactive Investors · 16 Oct 2026positive

Tiziana Life Sciences said the last patient has begun dosing in its randomized, placebo-controlled Phase 2 trial of intranasal foralumab for early or mild Alzheimer's disease, completing enrollment and dosing initiation for all participants. Topline data are expected in the first quarter of 2027.

Why it matters — The completed dosing milestone advances the trial, with topline results expected in the first quarter of 2027.

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease

GlobeNewsWire · 16 Oct 2026positive

Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled trial of intranasal foralumab for early/mild Alzheimer’s disease. The company anticipates topline data in Q1 2027.

Why it matters — The update marks completion of patient enrollment into dosing in this trial, with topline results expected in Q1 2027.

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Proactive Investors · 30 Sept 2026positive

Tiziana Life Sciences has submitted a request to the US Food and Drug Administration seeking orphan drug designation for its intranasal foralumab, a candidate therapy for multiple system atrophy (MSA), a rare neurodegenerative disease that currently has no approved disease-modifying treatments. MSA is a rapidly progressive disorder affecting autonomic and motor functions.

Why it matters — Obtaining orphan drug designation could offer regulatory advantages for Tiziana's intranasal foralumab and signal progress in addressing an unmet medical need in a rare disease.

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Proactive Investors · 28 Sept 2026positive

Tiziana Life Sciences announced that the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial for amyotrophic lateral sclerosis (ALS). The study, called the Healey ALS MyMatch BANYAN trial, is testing foralumab, a fully human anti-CD3 monoclonal antibody delivered as a nasal spray.

Why it matters — TLSA watchers will care because foralumab, the company's key candidate, has advanced to patient dosing in a Phase 2a ALS trial, marking a meaningful clinical milestone for the pipeline.

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Proactive Investors · 21 Sept 2026neutral

Tiziana Life Sciences announced that the last patient has completed their final visit in the Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis. The randomized, double-blind, placebo-controlled trial enrolled 48 patients across three cohorts at multiple leading U.S. sites.

Why it matters — This marks a key milestone in the progression of the foralumab trial, bringing TLSA closer to potential data from its Phase 2a study in patients with na-SPMS.

FAQ

Frequently asked questions about TLSA stock

What is the TLSA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) have a median 12-month price target of $8.03, with estimates ranging from $7.03 to $9.03. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSA stock a buy right now?

Of the 2 analysts covering Tiziana Life Sciences Ltd. (Bermuda), 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 20 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSA?

As at 29 Oct 2026, Tiziana Life Sciences Ltd. (Bermuda) ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will TLSA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +787.9% from the last close, and Ticker Nerd's factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 20 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSA stock forecast for 2030?

No analyst covering Tiziana Life Sciences Ltd. (Bermuda) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.03 to $9.03 over the next 12 months.

How has TLSA stock performed over the past year?

Tiziana Life Sciences Ltd. (Bermuda) returned -52.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tiziana Life Sciences Ltd. (Bermuda) do?

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders.

What is the latest news on TLSA?

The most recent item we track (Proactive Investors, 16 Oct 2026): "Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab". Tiziana Life Sciences said the last patient has begun dosing in its randomized, placebo-controlled Phase 2 trial of intranasal foralumab for early or mild Alzheimer's disease, completing enrollment and dosing initiation for all participants. Topline data are expected in the first quarter of 2027.

Company

About Tiziana Life Sciences Ltd. (Bermuda).

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.

CEO Dr. Ivor R. Elrifi Ph.D. · 10 employees · United Kingdom · https://www.tizianalifesciences.com